20 July 2020
- Patients who received SNG001 had a 79% lower risk of developing severe disease, compared to placebo
- Patients who received SNG001 were more than twice as likely to recover from COVID-19 as those on placebo
tranScrip has provided a range of specialist support services to Synairgen for over 10 years. It has been involved in the COVID-19 programme since the beginning and is pleased to announce positive results from the clinical trial of SNG001, Synairgen’s wholly owned inhaled formulation of interferon beta (IFN-beta), in hospitalised COVID-19 patients.
SNG001, an inhaled formulation of IFN-beta, a naturally occurring antiviral and anti-inflammatory protein, has to date been investigated in virus induced exacerbations of asthma and COPD. Systemic IFN-beta is widely used for treating multiple sclerosis.
Richard Marsden, CEO of Synairgen, said: “We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised COVID-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’. It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2. In addition, SNG001 has significantly reduced breathlessness, one of the main symptoms of severe COVID-19. This assessment of SNG001 in COVID-19 patients could signal a major breakthrough in the treatment of hospitalised COVID-19 patients. Our efforts are now focused on working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible.”
The double-blind placebo-controlled trial recruited 101 patients from 9 specialist hospital sites in the UK during the period 30 March to 27 May 2020.More data is in Synairgen’s press release
Dr Flic Gabbay, Managing Partner of tranScrip, said: “We are excited to see the results, which demonstrate not only more patients improving by the study endpoint but also a clinically important reduction in the number of patients becoming worse. We are looking forward to supporting the company through the next phase of development and interactions with regulators.”
Full PR available here.